

Palo Alto Networks (PANW US)

Platformization strategy resonating well with customers

Palo Alto Networks (PANW) announced 1QFY25 (Jul year-end) results: total revenue was up 13.9% YoY to US\$2.1bn, 1% ahead of Bloomberg consensus, and non-GAAP net income reached US\$544.9mn, up 17% YoY, 6% better than consensus, driven by more optimized-than-expected sales and marketing and G&A spend aided by operating efficiency improvement. The accelerated Platformization strategy is delivering early-stage results, in our view, and should help drive its long-term market share gains. Our FY25E revenue/non-GAAP net profit are lifted by 0.3%/2.2% to factor in better-than-expected results. We roll over our valuation period to 2025E, and raise our target price by 17% to US\$464.4 based on an unchanged EV/sales multiple of 16.0x. Maintain BUY.

- Solid 1QFY25 results better than market expectation. In 1QFY25, subscription and support revenue grew 16% YoY to US\$1.8bn, inline with consensus, and accounted for 83% of PANW's total revenue (1QFY24: 82%), driven by the solid increase in client adoption of NGS products. NGS ARR reached US\$4.52bn by the end of 1QFY25, up 40% YoY. Non-GAAP OP reached US\$616.2mn, and translated into a 28.8% non-GAAP OPM, 1.2ppts better than consensus, driven by more optimized-than-expected sales and marketing and G&A spend. Revenue/non-GAAP OP for 1QFY25 were 1%/5% better than Bloomberg consensus. We estimate 2QFY25 total revenue of US\$2.23bn, up 13% YoY, driven by solid subscription and support revenue growth.
- NGS products continued to deliver solid growth. In terms of key operating metrics: 1) the no. of active SASE customers saw 20% YoY growth, and over 40% of the new SASE customers were new to PANW in 1QFY25; also, the number of SASE US\$1mn+ deals was up 40% YoY; 2) Cortex crossed US\$1.0bn in ARR with strength driven by XSIAM; currently 40 XSIAM customers have an ARR profile of over US\$1mn, up 180% YoY. We forecast NGS ARR to grow 35% YoY to US\$4.7bn in 2QFY25, driven by continued penetration of SASE and XSIAM products.
- Platformization strategy is resonating well among customers. As of end-1QFY25, PANW had achieved 1,100 (4QFY24: >1000) total Platformizations with >70 QoQ net adds (4QFY24: >90) among its top 5k customers. Management highlighted a 6% increase in the NGS ARR per platformized customer in 1QFY25 compared with FY24. We remain constructive that accelerated Platformization should help drive PANW's market share gains as well as margin expansion over the long-term, as it can help optimize the cost of sales.
- Update on FY25 guidance. Due to the upbeat 1QFY25 results, and sustained solid business performance, management lifted FY25 guidance: 1) NGS ARR to US\$5.52bn-5.57bn (from US\$5.42bn-5.47bn); 2) total revenue to US\$9.12bn-9.17bn (from US\$9.10bn-9.15bn); and 3) diluted non-GAAP EPS to US\$6.26-6.39 (from US\$6.18-6.31).

l	Еa	rn	IIN	gs	5	un	nm	nar	У

Earnings Summary										
(YE 31 Jul)	FY23A	FY24A	FY25E	FY26E	FY27E					
Revenue (US\$ mn)	6,893	8,028	9,149	10,641	12,274					
YoY growth (%)	25.3	16.5	14.0	16.3	15.3					
Net profit (US\$ mn)	439.7	2,577.6	1,436.2	1,786.2	2,321.6					
Adjusted net profit (US\$ mn)	1,440.0	1,948.1	2,261.3	2,652.6	3,142.0					
YoY growth (%)	79.4	35.3	16.1	17.3	18.5					
EPS (Adjusted) (US\$)	4.43	5.67	6.45	7.48	8.76					
Consensus EPS (US\$)	na	na	6.28	7.23	8.60					
Source: Company data, Bloomber	Source: Company data, Bloomberg, CMBIGM estimates									

BUY (Maintain)

Target Price US\$464.40 (Previous TP US\$398.70) Up/Downside 16.8% **Current Price** US\$397.70

US Internet & Software

Saivi HE, CFA (852) 3916 1739 hesaiyi@cmbi.com.hk

Ye TAO, CFA franktao@cmbi.com.hk

Wentao LU, CFA luwentao@cmbi.com.hk

Stock Data

139,500.5
384.7
402.36/261.97
350.8

Source: FactSet

Shareholding Structure Vanguard Group Inc 30.8% Blackrock Inc 25.8%

Source: Nasdaq

Share Performance

	Absolute	Relative
1-mth	5.7%	3.6%
3-mth	13.8%	5.7%
6-mth	28.9%	14.2%

Source: FactSet

12-mth Price Performance



Source: FactSet



Figure 1: PANW: quarterly results trend

						1QFY25	Diff%
(US\$ mn)	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	consensus	
Revenue	1,878	1,975	1,985	2,190	2,139	2,120	0.9%
Growth - YoY	20.1%	19.3%	15.3%	12.1%	13.9%		
Product revenue	341	391	391	481	354	344	2.9%
Growth - YoY	3.4%	10.7%	0.7%	-5.3%	3.7%		
Subscription and support revenue	1,537	1,584	1,594	1,709	1,785	1,778	0.4%
Growth - YoY Subscription revenue as % of	24.6%	21.7%	19.6%	18.2%	16.1%		
total revenue	81.8%	80.2%	80.3%	78.1%	83.5%		
Gross profit	1,465.8	1,538.7	1,538.6	1,680.8	1,651.9	1,643.7	0.5%
GAAP R&D expenses	409.5	447.9	457.2	494.8	480.4	467.3	
GAAP S&M expenses	660.5	673.0	718.7	742.3	720.1	732.8	
GAAP G&A expenses	120.1	301.5	118.6	140.3	97.7	128.2	
Operating profit - GAAP	215.2	53.6	176.7	238.4	286.5	240.5	19.1%
Net profit - GAAP	194.2	1,746.9	278.8	357.7	350.7	268.8	30.5%
Operating profit - non-GAAP	529.3	564.2	507.9	588.3	616.2	585.5	5.2%
Net profit - non-GAAP	466.3	504.7	454.9	522.2	544.9	516.0	5.6%
Growth - YoY	75.0%	52.2%	26.6%	8.2%	16.9%		
<u>Margins</u>							
GPM	78.0%	77.9%	77.5%	76.8%	77.2%	77.5%	-0.3 ppt
R&D expenses ratio	21.8%	22.7%	23.0%	22.6%	22.5%	22.0%	0.4 ppt
S&M expenses ratio	35.2%	34.1%	36.2%	33.9%	33.7%	34.6%	-0.9 ppt
G&A expenses ratio	6.4%	15.3%	6.0%	6.4%	4.6%	6.1%	-1.5 ppt
OPM	11.5%	2.7%	8.9%	10.9%	13.4%	11.3%	2.1 ppt
NPM	10.3%	88.4%	14.0%	16.3%	16.4%	12.7%	3.7 ppt
Non-GAAP OPM Non-GAAP NPM	28.2% 24.8%	28.6% 25.6%	25.6% 22.9%	26.9% 23.9%	28.8% 25.5%	27.6% 24.3%	1.2 ppt 1.1 ppt

Source: Bloomberg, CMBIGM

Figure 2: PANW: changes in CMBI forecast

Current			F	Previous		Change (%)			
US\$ mn	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	9,148.8	10,641.2	12,273.8	9,124.3	10,664.8	12,300.3	0.3%	-0.2%	-0.2%
Gross profit	6,814.9	8,031.3	9,297.4	6,840.7	8,044.8	9,313.2	-0.4%	-0.2%	-0.2%
Non-GAAP net profit	2,261.3	2,652.6	3,142.0	2,220.8	2,721.0	3,134.9	1.8%	-2.5%	0.2%
Gross margin	74.5%	75.5%	75.7%	75.0%	75.4%	75.7%	-0.5 ppt	0.0 ppt	0.0 ppt
Non-GAAP net margin	24.7%	24.9%	25.6%	24.3%	25.5%	25.5%	0.4 ppt	-0.6 ppt	0.1 ppt

Source: CMBIGM estimates

Figure 3: PANW: CMBI forecast vs Bloomberg consensus

		Current		Consensus			Diff (%)			
US\$ mn	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	
Revenue	9,148.8	10,641.2	12,273.8	9,131.0	10,595.7	12,227.3	0.2%	0.4%	0.4%	
Gross profit	6,814.9	8,031.3	9,297.4	7,067.1	8,208.3	9,479.4	-3.6%	-2.2%	-1.9%	
Non-GAAP net profit	2,261.3	2,652.6	3,142.0	2,213.6	2,609.0	3,086.3	2.2%	1.7%	1.8%	
Gross margin	74.5%	75.5%	75.7%	77.4%	77.5%	77.5%	-2.9 ppt	-2.0 ppt	-1.8 ppt	
Non-GAAP net margin	24.7%	24.9%	25.6%	24.2%	24.6%	25.2%	0.5 ppt	0.3 ppt	0.4 ppt	

Source: Bloomberg, CMBIGM estimates



Figure 4: PANW: target valuation

EV/S Valuation (US\$mn)	2025E
2025E Revenue (3QFY25-2QFY26)	9,888
Target EV/Sales	16.0x
Enterprise value	158,200
+ net cash	4,691
Equity value	162,891
No. of shares outstanding (diluted; mn)	351
Target price (US\$)	464.4

Source: Company data, CMBIGM estimates



Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Jul (US\$ mn)						· · · · · · · · · · · · · · · · · · ·
Revenue	5,502	6,893	8,028	9,149	10,641	12,274
Cost of goods sold	(1,719)	(1,910)	(2,059)	(2,334)	(2,610)	(2,976)
Gross profit	3,783	4,983	5,968	6,815	8,031	9,297
Operating expenses	(3,972)	(4,596)	(5,284)	(5,645)	(6,324)	(7,045)
Selling expense	(2,149)	(2,544)	(2,795)	(3,127)	(3,517)	(3,962)
Admin expense	(405)	(448)	(681)	(521)	(583)	(619)
R&D expense	(1,418)	(1,604)	(1,809)	(1,997)	(2,223)	(2,464)
Operating profit	(189)	387	684	1,170	1,708	2,252
Other income	9	206	313	342	322	392
Interest expense	(27)	(27)	(8)	(4)	(4)	(3)
Pre-tax profit	(207)	566	988	1,508	2,026	2,642
Income tax	(60)	(127)	1,589	(72)	(240)	(320)
Others	0	Ô	0	0	0	0
Net profit	(267)	440	2,578	1,436	1,786	2,322
Adjusted net profit	803	1,440	1,948	2,261	2,653	3,142
BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Jul (US\$ mn)						
Current assets	6,415	6,048	6,850	10,188	15,234	22,052
Cash & equivalents	2,119	1,135	1,535	4,228	8,367	14,107
Account receivables	2,143	2,463	2,619	2,974	3,590	4,331
Other current assets	2,154	2,450	2,696	2,985	3,277	3,613
Non-current assets	5,839	8,453	13,141	14,958	15,871	15,918
PP&E	358	355	361	405	479	598
Deferred income tax	0	0	0	0	0	0
Investment in JVs & assos	1,052	3,048	4,173	4,120	4,120	4,120
Intangibles	385	315	375	688	525	362
Goodwill	2,748	2,927	3,350	4,051	4,051	4,051
Other non-current assets	1,297	1,809	4,882	5,695	6,697	6,788
Total assets	12,254	14,501	19,991	25,146	31,105	37,970
Current liabilities	8,306	7,738	7,683	9,117	10,740	12,307
Account payables	128	132	116	132	145	168
Other current liabilities	7,318	6,666	6,505	7,593	8,988	10,814
Accrued expenses	860	939	1,061	1,393	1,606	1,325
Non-current liabilities	3,737	5,015	7,139	8,141	9,482	11,236
Long-term borrowings	0	0	0	0	0	0
Other non-current liabilities	3,737	5,015	7,139	8,141	9,482	11,236
Total liabilities	12,044	12,753	14,821	17,258	20,222	23,543
Retained earnings	(1,667)	(1,227)	1,350	3,623	5,410	7,731
Other reserves	1,877	2,976	3,820	4,265	5,474	6,696
Total shareholders equity	210	1,748	5,170	7,888	10,884	14,427
Minority interest	0	0	0	0	0	0
Total equity and liabilities	12,254	14,501	19,991	25,146	31,105	37,970



					A Wholly Owned !	ubsidiary Of Chiza Merchania Fu
CASH FLOW	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Jul (US\$ mn)						
Operating						
Profit before taxation	(207)	566	988	1,508	2,026	2,642
Depreciation & amortization	283	282	283	318	312	302
Tax paid	(60)	(127)	1,589	(72)	(240)	(320)
Change in working capital	521	563	910	699	(589)	2,153
Others	1,448	1,492	(513)	1,158	2,853	1,222
Net cash from operations	1,985	2,778	3,258	3,612	4,362	5,998
Investing						
Capital expenditure	(193)	(146)	(157)	(201)	(223)	(258)
Others	(741)	(1,888)	(1,353)	(500)	0	0
Net cash from investing	(933)	(2,034)	(1,510)	(700)	(223)	(258)
Financing						
Share repurchases	(892)	(273)	(567)	0	0	0
Others	86	(1,454)	(776)	(220)	0	0
Net cash from financing	(807)	(1,726)	(1,343)	(220)	0	0
Net change in cash						
Cash at the beginning of the year	1,874	2,119	1,135	1,535	4,228	8,367
Exchange difference	0	0	0	0	0	0
Others	(0)	(1)	(5)	2	0	0
Cash at the end of the year	2,119	1,135	1,535	4,228	8,367	14,107

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

: Stock with potential return of over 15% over next 12 months BUY HOLD Stock with potential return of +15% to -10% over next 12 months SELL NOT RATED : Stock with potential loss of over 10% over next 12 months

: Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.